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DNA damageBcl-2 associated athanogene 3 (BAG3) has a modular structure that contains a BAG domain, a WW domain, a
proline-rich (PxxP) domain tomediate potential interactions with chaperons and other proteins that participate
in more than one signal transduction. In search for novel interacting partners, the current study identiﬁed that
78 kDa glucose-regulated protein (GRP78) was a novel partner interacting with BAG3. Interaction between
GRP78 and BAG3 was conﬁrmed by coimmunoprecipitation and glutathione S-transferase (GST) pulldown. We
also identiﬁed that the ATPase domain of GRP78 and BAG domain of BAG3 mediated their interaction. Counter-
intuitive for a prosurvival protein, BAG3 was found to promote the cytotoxicity of breast cancer MCF7, thyroid
cancer FRO and glioma U87 cells subjected to genotoxic stress. In addition, the current study demonstrated
that BAG3 interfered with the formation of the antiapoptotic GRP78-procaspase-7 complex, which resulted in
an increased genotoxic stress-induced cytotoxicity in cancer cells. Furthermore, overexpression of GRP78 signif-
icantly blocked the enhancing effects of BAG3 on activation of caspase-7 and induction of apoptosis by genotoxic
stress. Overall, these results suggested that through direct interaction BAG3 could prevent the antiapoptotic
effect of GRP78 upon genotoxic stress.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Bcl-2 associated athanogene (BAG) co-chaperone proteins share
a conserved BAG domain with 110–124 amino acids, through which
they bind to the ATPase domain of heat shock protein 70 (HSP70) [1].
In addition, they can bind other partners, including Bcl-2, steroid
hormone receptors, Raf-1 and others [2,3]. In humans, there are six
BAG family members, BAG1–6 [1]. Among them, BAG3, also known
as CAIR-1 or Bis, is induced in many cell types and believed to serve
as a protective mechanism upon cellular stress [1–7]. In normal
cells, BAG3 expression is very low, while its expression is increased
in many neoplastic cell types, including leukemia, lymphoma, mye-
loma, melanomas, glioblastoma, pancreas and thyroid carcinomas
[8–13]. Several lines of evidence indicate that BAG3 plays a role in
survival of human cancer cells, and its down-modulation enhances
chemotherapy-mediated apoptosis of cancer cells [4,6,9,10,14–20].
In addition, the multifaceted functions of BAG3 have been describedtry & Molecular Biology, China
yang 110001, China. Tel.: +86
ang).
ights reserved.in regulating cell cycle, apoptosis and survival, migration and adhesion,
and viral replication [21–23].
BAG3 is a 74-kDa cytoplasmic protein mainly localized in the rough
endoplasmic reticulum [2,14]. Similar like other co-chaperones, BAG3
has a modular structure that contains three protein interaction motifs:
a WW domain, a proline-rich (PxxP) domain, and a BAG domain to
mediate potential interactions with chaperones and/or other proteins
[1,2,23,24]. In the current study, we sought to search for novel inter-
active protein partners of BAG3 and revealed that BAG3 forms complex
with the 78-kDa glucose-regulated protein (GRP78). GRP78, also re-
ferred to as BiP/HSPA5, is a central regulator of endoplasmic reticulum
function and induction of GRP78 has been widely used as a marker
for endoplasmic reticulum stress and the onset of the unfolded protein
response [25].
GRP78 is upregulated and plays a critical role in promoting cancer
initiation, progression and therapeutic resistance [26–32]. Aberrant in-
duction of GRP78 is correlated with resistance to chemotherapeutic
agents, such as 5-ﬂuorouracil, doxorubicin, etoposide, and adriamycin
[33–35]. It is believed that GRP78 confers resistance to chemotherapy-
induced apoptosis in cancer cells, at least, in part, via physical inter-
action with procaspase-7 to prevent its activation, a function that is
dependent on the GRP78 ATP-binding domain [33].
To investigate physical function of GRP78 and BAG3 interaction, we
generated MCF7, FRO and U87 cells stably expressing exogenous BAG3.
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overexpression sensitized MCF7, FRO and U87 cells to etoposide
and adriamycin-induced cytotoxicity. In addition, we demonstrated
that BAG3 facilitated caspase-7 activation by competitively forming
complex with GRP78 and promoting dissociation of procaspase-7
from GRP78.
2. Materials and methods
2.1. Culture of cell lines
HEK293, MCF7, FRO and U87 cell lines were maintained in DMEM
(Sigma-Aldrich, Saint Louis, MO) and supplemented with 10% fetal
bovine serum (FBS, ExCell Biology Inc., Shanghai, China).
2.2. Immunoblotting and coimmunoprecipitation assay
Cells were disrupted in lysis buffer [50 mM Tris (pH 7.5), 5 mM
EDTA, 150 mMNaCl, 1 mMDTT, 0.01% NP40, 0.02 mMPMSF, 1× prote-
ase inhibitors]. 500 μg of total protein extract from each sample was
pretreatedwith protein G-Sepharose beads (Upstate), followed by incu-
bation with 5 μg of mouse anti-GRP78 or mouse anti-Flag M2 antibody
(Sigma-Aldrich). For negative controls, the mouse immunoglobulin G
(IgG, Santa Cruz Biotechnology) was used. The proteins were resolved
by SDS-PAGE and then subjected to Western blot analysis.
2.3. Peptide mass ﬁngerprinting
Coomassie-stained protein bands were excised, equilibrated with a
reduction buffer (0.5 M Tris, pH 8.5, 8 M guanidine hydrochloride,
0.3% EDTA, 5% acetonitrile), and digested with 1 pmol of lysyl endo-
peptidase (Wako) in 6 μl of digestion buffer (18 mM Tris, pH 8.9, 70%
acetonitrile) for 90 min at 37 °C. Acetonitrile was added to a ﬁnal
concentration of 90%, and the sample was desalted and concentrated
using ZipTip HPL (Millipore Corp., Bedford, MA). Peptides were eluted
with 1 μl of matrix solution (0.1% acetic acid, 50% acetonitrile saturated
with α-cyano-4-hydroxycinnamic acid) and applied onto a sample
plate (Applied Biosystems). Matrix-assisted laser desorption ionization
time-of-ﬂight (MALDI-TOF) mass spectrometry was performed using a
Voyager-DE PRO (PerSeptive Biosystems). Ions speciﬁc for each sample
were then used to interrogate human protein sequences in the NCBInr
data base using the MASCOT (available on the World Wide Web at
www.matrixscience.com) data base search algorithms.
2.4. Production and puriﬁcation of recombinant human GRP78 and
BAG3 in bacteria
High level expression of recombinant human GRP78 and BAG3 was
achieved in bacteria. Brieﬂy, transformed Rosetta (DE3) cells containing
the GRP78-pET-28b or BAG3-pET-28b construct were grown at 16 °C
in LB media and treated with isopropyl β-D-1-thiogalactopyranoside
to induce GRP78 or BAG3 expression. GRP78 or BAG3 was puriﬁed by
using Glutathione sepharose 4B (GE).
2.5. Glutathione S-transferase pull-down assays
Glutathione S-transferase (GST)-GRP78 and GST-BAG3 were
constructed by subcloning full-length human GRP78 and BAG3
cDNA into pGEX 4T1, respectively. GST-GRP78, GST-BAG3, and GST
were expressed in Escherichia coli BL21 and puriﬁed. Five micro-
grams of GST-BAG3, GST-GRP78, and GST bound to glutathione-
Sepharose beads (Sigma-Aldrich) were incubated with 500 μg of
total protein extract on a rotating shaker at 4 °C for 16 h. The beads
were collected by centrifugation at 2000 rpm for 5 min and washed
thrice with extraction buffer. The bound proteinswere eluted in SDS-PAGE sample loading buffer and subjected to SDS-PAGE andWestern
blotting.
2.6. Immunoﬂuorescence (IF) staining and ﬂuorescence microscopy
Cellswereﬁxedwith 4%paraformaldehyde, permeabilized for 5 min
with PBS containing 0.1% Triton X-100 and blocked with 1% BSA.
Immunostaining was performed using the appropriate primary
and secondary antibodies, and images were acquired using an Olympus
ﬂuorescence microscope.
2.7. DNA constructs and generation of stable cell lines
A cDNA encoding human BAG3 or GRP78 was generated by
PCR from human brain cDNA library (Invitrogen) and subcloned
into the eukaryotic expression plasmid pcDNA3. The construct was
veriﬁed by DNA sequencing. A short hairpin RNA (shRNA) against
BAG3 (shBAG3) was purchased from Open Biosystems. MCF7, FRO, or
U87 cells were transfected with BAG3 construct using Lipofectamine
2000 according to the manufacturer's instruction and stable clonal
cell lines were selected with 1 mg/ml G418, and were maintained at
0.2 mg/ml G418.
2.8. Cell viability assays
For cell viability assays, cells were plated in 96-well dishes
(1 × 104 cells per well) and the next day were treated with or with-
out genotoxic stress inducing agents in 10% FBS-containing media
and grown over a 24-h period. Cell viability was assessed using the
3-(4,5-dimethylthiazol-2-thiazolyl)-2,5-diphenyl tetrazolium bromide
(MTT) assay (Chemicon, Bedford, MA) according to the manufacturer's
instruction.
2.9. Detection of apoptotic cell death
For apoptotic cell death assays, cells were washed twice in
phosphate-buffered saline and then stained with Annexin V-FITC
(Biovision, Mountainview, CA) and propidium iodide (PI, Sigma-
Aldrich) according to the manufacturer's instructions. After staining
with Annexin V-FITC and PI, samples were analyzed by ﬂuorescence-
activated cell scanner (FACScan) ﬂow cytometer (Becton Dickinson,
Franklin Lakes, NJ).
2.10. Caspase-7 activity assay
Cell lysates were prepared using CHAPS lysis buffer (50 mM
HEPES, pH7.4, 0.1% CHAPS, 0.1% Triton X-100, 0.1 mM EDTA, and
1 mM dithiothreitol) and 12,000× g centrifugation at 4 °C. DEVDase
activity was measured using the speciﬁc ﬂuorogenic substrate, Asp-
Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-AMC, Sigma) in
assay buffer (50 mM HEPES pH 7.4, 100 mM NaCl, 0.1% CHAPS, 10%
glycerol, 1 mM EDTA, and 10 mM dithiothreitol), and real-time re-
cordings of enzyme-catalyzed AMC release were obtained using a
ﬂuorescence plate reader. Fluorescence values were converted to pi-
comoles of AMC release using a standard curve generated with free
AMC and the maximum rate of AMC release (pmol/min/mg protein)
was calculated.
2.11. Statistics
The statistical signiﬁcance of the difference was analyzed by
ANOVA and post hoc Dunnett's test. Statistical signiﬁcance was
deﬁned as P b 0.05. All experiments were repeated three times, and
data were expressed as the mean ± SD (standard deviation) from a
representative experiment.
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Fig. 1. BAG3 interacts with GRP78. A, BAG3 immunocomplexes from HEK293 cells transfected with Flag-tagged BAG3 were resolved by SDS-PAGE and stained with Coomassie blue.
Coomassie-stained protein bands were analyzed using peptide mass ﬁngerprinting. The star denotes a prominent polypeptide of ~78 kDa and polypeptides of GRP78 identiﬁed by
mass spectrometry are summarized. B, HEK293 cells were transiently transfectedwith expression vectors for Flag-tagged BAG3 and His-tagged GRP78, reciprocal coimmunoprecipitation
of BAG3 and GRP78 was performed. C, coimmunoprecipitation of endogenous GRP78 with endogenous BAG3 was performed using cell lysates isolated from the indicated cell lines.
D, Coomassie blue staining of GST, GST-BAG3 and GST-GRP78 resolved by SDS-PAGE. E, HEK293 cells were co-transfected with BAG3 and GRP78 eukaryotic expression vectors and
cell extracts were incubated with GST-BAG3, GST-GRP78, or GST-linked beads. The bound proteins were resolved by SDS-PAGE and probed for GRP78 or BAG3 by western blot.
F, HEK293 cell extracts were incubated with GST-BAG3, GST-GRP78, or GST-linked beads. The bound proteins were resolved by SDS-PAGE and probed for GRP78 or BAG3 by western
blot. G, FRO cells were stained with GRP78 (red), BAG3 (green) and nucleus with DAPI (blue).
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3.1. GRP78 is a novel binding partner of BAG3
To identify novel proteins that interact with BAG3, a Flag-tagged form
of BAG3 was transiently expressed in HEK293 cells and complexes were
isolated by immunoprecipitation (IP) with an anti-Flag antibody. Isolated
immunocomplexes were analyzed by SDS-PAGE and Coomassie blue
staining, and a prominent polypeptide of 78-kDa apparent molecular
mass was speciﬁcally detected in association with BAG3 (Fig. 1A).
Peptide mass ﬁngerprinting unambiguously identiﬁed the polypeptide
as GRP78/HSPA5/BiP, based on 12 peptides with sequence coverage of
21.4% (Fig. 1A).
To verify the observed interaction between BAG3 and GRP78,
Flag-tagged BAG3 and His-tagged GRP78 were expressed in HEK293
cells. Reciprocal IP studies conﬁrmed the physical BAG3 interaction
with GRP78 (Fig. 1B). Coimmunoprecipitation (co-IP) of endogenous
proteins was also detected in several cell lines derived from differentA
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Fig. 2. BAG domain of BAG3 interacts with ATPase domain of GRP78. A, Schematic diagrams of
terminal GRP78 (GRP78-C). B, Coomassie blue staining of GST tagged GRP78-FL, GRP78-N, a
BAG3 eukaryotic expression vector and cell extracts were incubated with GRP78-FL, GRP78-N
anti-Flag antibody. D, Schematic diagrams of Flag-tagged wild-type (BAG3-WT), WW domain
(BAG3-ΔBAG) BAG3 eukaryotic constructs. E, HEK293 cells were cotransfected with His-tagge
using anti-Flag antibody. The bound proteins were subjected to Western blot using anti-Flag ahistology, including HEK293, MCF7, U87, HepG2 and FRO cells
(Fig. 1C). The interaction between GRP78 and BAG3 is speciﬁc because
this complex was not observed using control IgG as the precipitating
antibody (Fig. 1C).
To characterize the physical interaction between GRP78 and BAG3,
they were both expressed as bacterial GST-fusion proteins. The yield
and purity of the GST-proteins were conﬁrmed by Coomassie blue
staining (Fig. 1D). In pulldown assays, GST-BAG3, but not the GST pro-
tein, was able to bind GRP78 from BAG3 and GRP78 overexpressed
HEK293 cell extracts (Fig. 1E). Reversely, GST-GRP78, but not the GST
protein, was able to bind BAG3 from BAG3 and GRP78 overexpressed
HEK293 cell extracts (Fig. 1E). Similarly, GST-BAG3 and GST-GRP78
were able to pull down endogenous GRP78 and BAG3 from HEK293
cell extracts, respectively (Fig. 1F). Subcellular colocalization of en-
dogenous BAG3 and GRP78 proteins was also studied by immunoﬂu-
orescence in FRO cells (Fig. 1G). It is noteworthy that colocalization
analysis shows a partial overlapping in the subcellular distributions of
both proteins, as seen by the appearance of yellow immunoﬂuorescence0 400 500 651 654
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suggested that the interaction between BAG3 and GRP78 was direct and
speciﬁc.
3.2. The ATPase domain of GRP78 and the BAG domain of BAG3 mediate
their interaction
GRP78 is a highly conserved molecule containing 654 amino
acids, which include endoplasmic reticulum (ER) signal peptide
and an ATPase domain at the NH2-terminal, and a peptide-binding
domain and a KDEL motif at the COOH-terminal (Fig. 2A) [36]. As
the peptide-binding domain of GRP78 associates with folding interme-
diates in the ER lumen, it could interact with newly synthesized BAG3,
thereby compromising the functional importance of the BAG3–GRP78
interaction. To determine the interactive domain of GRP78 with
BAG3, we generated two truncated GRP78 constructs, NH2-terminal
(GRP78-N) construct containing ER signal peptide and ATPase domain,
and COOH-terminal (GRP78-C) construct containing peptide-binding
domain and KDEL motif (Fig. 2A). The yield and purity of GST-GRP78
proteins were determined by Coomassie blue staining (Fig. 2B). In
pulldown assays using GST-linked GRP78 and HEK293 cell extracts,
full-length GRP78 (GRP78-FL) and NH2-terminal GRP78 (GRP78-N),
but not COOH-terminal GRP78 (GRP78-C) were able to bind BAG3
from the cell extracts (Fig. 2C).A
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western blots.BAG3 is a co-chaperone molecule containing 575 amino acids,
which has a modular structure including three protein interaction
motifs: a WW domain, a proline-rich (PxxP) domain, and a BAG
domain (Fig. 2D) [1,2,23,24]. To determine the interactive domain
of BAG3 with GRP78, we generated three BAG3 mutant structures
which delete WW, PxxP, and BAG domain, respectively (Fig. 2D).
HEK293 cells were cotransfected with different Flag-tagged BAG3
and His-tagged GRP78 constructs, and co-IP was performed using
anti-Flag antibody. Similar like WT (wild type)-BAG3, ΔWW (WW
domain deleted)- and ΔPxxP (PxxP domain deleted)-BAG3 were
able to interact with GRP78, in contrast, ΔBAG (BAG domain deleted)-
BAG3 could not interact with GRP78 (Fig. 2E).
3.3. BAG3 and procaspase-7 competitively form complex with GRP78
To investigate the possibility that BAG3, GRP78 and procaspase-7
are in the same complex, HEK293 cells were co-transfected with
Flag-BAG3, His-GRP78 and Myc-procaspase-7 in the presence of
pancaspase inhibitor z-VAD-fmk and subjected to co-IP. Both BAG3
and procaspase-7 were pulled down by anti-His antibody (Fig. 3A).
No procaspase-7 was detected using anti-Flag antibody while BAG3
and GRP78 were found in the same immunoprecipitates (Fig. 3B).
Similarly, no BAG3 was detected using anti-Myc antibody while GRP78
and procaspase-7 were found in the same immunoprecipitates (Fig. 3C).Flag-BAG3
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complex with GRP78, raising the question whether BAG3 binding to
GRP78 can compete for interaction of procaspase-7 with GRP78. To
directly test this possibility, HEK293 cells were cotransfected with
GRP78, procaspase-7 and increasing amount of BAG3 expression
vector in the presence of zVAD-fmk. Western blot conﬁrmed that
BAG3 level was increased in a dose-dependent manner correlating
with the amount of transfected BAG3 expression vector (Fig. 3D). co-IPB
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accordingly, whereas the interaction of BAG3 with GRP78 decreased
(Fig. 3E).3.4. BAG3 renders cancer cells sensitive to etoposide and adriamycin
As GRP78 is a contributing factor for etoposide and adriamycin resis-
tance via interaction with procaspase-7 in cancer cells [27,30,31], to in-
vestigate the functional signiﬁcance of interaction between BAG3 and
GRP78,we generatedMCF7, FRO andU87 subline cells stably expressing
exogenous BAG3 or empty vector, respectively (Fig. 4A). MTT (Fig. 4B),
ﬂowcytometry (Fig. 4C) and trypan blue exclusion (Fig. 4D) demon-
strated that upregulation of BAG3 signiﬁcantly increased the respon-
siveness of MCF7, FRO and U87 cells to etoposide. Similar effects were
also observed for adriamycin treatment, as assessed by MTT (Fig. 4E).
To avoid inﬂuence of EGFP on BAG3 function, FRO cells were also tran-
siently transfected with empty or Flag-tagged BAG3 expression vector(Fig. 4F). Flowcytometry conﬁrmed that transient BAG3 overexpression
increased etoposide-induced apoptosis of FRO cells (Fig. 4G).
To examine the effect of BAG3 on caspase-7 activation medicated
by etoposide and adriamycin, caspase-7 processing was monitored by
Western blot with speciﬁc antibody that recognizes both procaspase-7
and active caspase-7. Treating MCF7, FRO and U87 cells with etoposide
and adriamycin resulted in activation of caspase-7, giving rise to 32-kDa
intermediate and 20-kDa active forms in the etoposide or adriamycin-
treated cells (Fig. 4H). The intermediate and active forms of caspase-7
were signiﬁcantly increased in BAG3-overexpressing cells (Fig. 4H).
Consistent with previous reports that BAG3 per se is a substrate of
caspases [37–39], etoposide and adriamycin resulted in cleavage
of BAG3 (Fig. 4H). A caspase-7 speciﬁc activity assay demonstrated
that DEVDase activity induced by etoposide was signiﬁcantly enhanced
in BAG3-overexpressing cells (Fig. 4I). It should be mentioned that
BAG3-overexpressing cells demonstrated about 2 folds of caspase-7 ac-
tivity under the basal condition (Fig. 4I). To investigate whether BAG3
expression affects endogenous interaction of GRP78 with procaspase-
7, we performed colocalization of endogenous GRP78 and procaspase-
7 in FRO cells. Immunoﬂuorescence demonstrated colocalization
of GRP78 and procaspase-7 was signiﬁcantly decreased in BAG3-
overxpressing FRO cells, when compared with parent FRO cells (Fig. 4J).
3.5. Involvement of GRP78 in the sensitizing effects of BAG3 on etoposide
and adriamycin-induced cytotoxicity of cancer cells
To elucidate the role of GRP78 in the context of its interaction
with BAG3, GRP78 expression was upregulated by transfection
with GRP78 eukaryotic vector. Western blots conﬁrmed that GRP78
expression level was signiﬁcantly enhanced by transfection with
GRP78 expression vector, but not an empty vector in both MCF7
and BAG3-overexpressing MCF7 cells (Fig. 5A). MTT assay (Fig. 5B)
and ﬂowcytometry (Fig. 5C) demonstrated that GRP78 overexpres-
sion signiﬁcantly suppressed sensitivity of both parental and BAG3-
overexpressing MCF7 cells to etoposide and adriamycin. Importantly,
GRP78 overexpression almost completely blocked the sensitizing effects
of BAG3, as parental and BAG3-overexpressingMCF7 cells demonstrated
similar responsiveness to etoposide and adriamycin upon GRP78 overex-
pression (Fig. 5B and C). GRP78 overexpression also completely blocked
the enhancing effects of BAG3 on etoposide-induced cytotoxicity of U87
(Fig. 5D) and FRO (Fig. 5E) cells.
4. Discussion
Studies on BAG3 illustrate its function in regulating multifaceted
physiological and pathological processes, including cell cycle, cell
survival, apoptosis, migration and invasion, autophagy et al. [21,23,24].
BAG3 can bind to many proteins through its protein interaction motifs,
resulting in regulation of their activity [15,22,40–45]. Therefore, the adap-
tor nature of itsmultifaceted ability to complexwithmanyproteinsmight
ascribe to the pleiotropic functions of BAG3. Given the complexity
of BAG3 interactions, we sought to gain functional insights by searching
for novel partners interacting with BAG3, and identiﬁed that BAG3
formed complexes with GRP78. The BAG3–GRP78 interaction was sub-
sequently veriﬁed by coimmunoprecipitation and GST pulldown assays.
GST pulldown and coimmunoprecipitation assays also demonstrated
that BAG3 and GRP78 binding was mediated by BAG domain of BAG3 at
COOH-terminal and ATPase domain of GRP78 at NH2-terminal.
GRP78 is a multifunctional protein which plays a central role in
ER protein folding and assembly, targeting misfolded protein for
degradation, ER calcium binding, maintaining ER homeostasis, and
controlling cell signaling and viability. Although GRP78 is constitu-
tively expressed in many cell types, its biosynthesis can be induced
by a wide variety of physiologic and pathologic stress. Due to its
antiapoptotic property, GRP78 induction represents an effective protec-
tive mechanism to promote cell survival [46]. GRP78 is also associated
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[26,30,31]. Therefore, we investigated the physiological signiﬁcance of
the BAG3–GRP78 interaction in the context of chemotherapy in cancer
cells. Counterintuitive for a pro-survival and anti-apoptotic protein,
the current study instead observed a signiﬁcance promotion of cytotox-
icity in BAG3 overexpressing cells that had been subjected to etoposide
and adriamycin treatment. A large amount of studies have established
that GRP78 promotes therapeutic resistance of cancer cells via direct
binding with the cytosolic procaspase-7 via its ATP-binding domain
and blocks cleavage of procaspase-7 to its active form [26,29–31,33].
On the contrary, disruption of GRP78-procaspase-7 complex formation
enhances caspase-7 activation and increases in apoptosis [47,48]. The
current study demonstrated that BAG3 interfered with the formation
of the antiapoptotic GRP78-procaspase-7 complex. GRP78 upregulation
completely blocked the effect of BAG3 on increasing cytotoxicity and
caspase-7 activation induced by etoposide and adriamycin, indicating
that the sensitizing effect of BAG3 is ascribed to the disruption of
GRP78-procaspase-7 formation. It has been shown that BAG3 per se is a
substrate for caspases and cleaved at Asp347 site by caspases upon
apoptosis [38,39,49]. In consistent with these reports, the current studyalso demonstrated that etoposide and adriamycin increased expression
of the truncated BAG3. Although in the current study, BAG3 was not
found to interact with procaspase-7 using reciprocal immunoprecipita-
tion, it could not exclude that BAG3 is not a substrate for caspase-7
at present, as BAG3 may possibly interact with activated caspases-7.
However, since BAG domain is enough to mediate its interaction with
GRP78, cleavage of BAG3 by caspasesmight not inﬂuence its interaction
with GRP78 as long as the integrity of BAG domain is reserved.
Despite numerous reports suggesting that BAG3 can act as a pro-
liferative and anti-apoptotic molecule in various cancer cells, the
current study instead demonstrated signiﬁcantly sensitizing effects
of BAG3 on cytotoxicity of cancer cells induced by DNA damaging re-
gents etoposide and adriamycin. Consistent with our study, a previous
study performed in differentiation of HL-60 cells also supported that
BAG3may speciﬁcally have an anti-proliferative role [50]. This paradox-
ical effect may reﬂect the complexity of BAG3 interacting components,
and BAG3's effects may be closely related to cellular context. As a fact,
contradicting roles of BAG3 in cancer cell motility and invasion has also
been suggested [45,51–53]. A possible explanation of this contradiction
might be ascribed to the different cell lines used in the different reports.
3253D.-H. Kong et al. / Biochimica et Biophysica Acta 1833 (2013) 3245–3253Recently, we have described that phosphorylation status of BAG3 at
Ser187 site plays a critical role in regulation of epithelial–mesenchymal
transition(EMT) and invasion of thyroid cancer cells, as phosphorylated
BAG3 and non-phosphorylated BAG3 demonstrated completely contrary
effects [54], providing an alternative mechanism responsible for the
different phenotypic effects of BAG3 on cell motility and invasion. The
current study demonstrated that BAG3 and procaspase-7 form separate
complex with GRP78, and BAG3 and procaspase-7 competitively inter-
acts with GRP78.More experiments, for example, whether phosphoryla-
tion of BAG3 affects its interaction with GRP78, are necessary to clarify
the underlying mechanisms responsible for the different phenotypic
effects of BAG3 on cell survival, motion and invasion.
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